MGMT and central nervous system cancer: With advances in targeted tumor treatment research and technology, there have been several breakthroughs in the identification of glioma molecular markers, such as isocitrate dehydrogenase (IDH) mutations [3] and O6-methylguanine-DNA methyltransferase (MGMT O6) promoter methylation [4].